Erectile Dysfunction Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Erectile Dysfunction Drugs Market is Segmented by Product (Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn, and vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), and Other Products), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Erectile Dysfunction Drugs Market Overview
Study Period: 2018-2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: -3.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The erectile dysfunction drugs market was valued at approximately USD 3625 million in 2020, and it is projected to reach USD 2948 million by 2026, registering a CAGR of nearly -3.4% during the forecast period, 2021-2026.

The severe shortage of critical medical needs and the rapid increase in the number of cases of COVID-19 cases have led to a shift in the progress of health facilities. Tourism restrictions and the supply chain disruption have created a small negative impact on market players, leading to severe drug shortages in global markets. Lockdown and government restrictions have hampered the export and import of drugs across the countries due to the shortage of medicines, with many people being denied access to drugs.

Some factors that drive the erectile dysfunction (ED) drugs market include the adoption of a sedentary lifestyle and its associated stress, the rising geriatric population, and the comorbidity between erectile dysfunction and heart disease and diabetes. A sedentary lifestyle, alcoholism, and smoking greatly increase the risk of erectile dysfunction. Increased acceptance of these negative lifestyle decisions will lead to the full growth of the market.

Erectile dysfunction is the most common risk factor in men, and its incidence increases with age. Aging and older men frequently have comorbidities, like diabetes mellitus, chronic obstructive pulmonary disease, hypertension, and cardiovascular diseases, etc., likewise, they concurrently refer to a clinician for impairments in sexual function, mostly for erectile dysfunction (ED).

The rise in the number of ED cases is often correlated with the high growth of obesity, diabetes, and cardiovascular disorders. Hypertension is additionally another major illness linked to male erectile dysfunction, and as reported by CDC in 2018, the prevalence of hypertension has grown at a substantial rate, with approximately 65 million people affected by the condition within the United States.

However, the patients are reluctant to seek treatment, and this factor is restraining the market growth. Generally, ED is considered as a physical problem, and it is also due to poor psychological health. Most patients suffering from erectile dysfunction do not choose treatment options. This is a direct result of the social stigma associated with erectile dysfunction. In a number of low- and middle-income countries, social discrimination is particularly prevalent, where men and women suffer from silent sexual dysfunction, shame, guilt, and negligence/ignorance. Since ED is associated with a number of chronic diseases and a vast majority of people are affected by the disease, the treatment is mainly for chronic diseases, and patients often hide their sexual dysfunction. In addition, the intense competition offered by generic drugs with branded products greatly affects the market growth. Most of the branded products, especially Pfizer's Viagra, have lost their patent rights, and many generics have evolved since then, posing a great threat to the declining growth of the market. As a result of these factors, the market is experiencing a slowdown in growth.

Scope of the Report

As per the scope of this report, erectile dysfunction is a very common condition, and it can be defined as the inability to maintain an erection sufficient for sexual intercourse. The drugs used in the treatment of ED are covered under the scope of the report. The market is segmented by product (Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn, and vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), and other products), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Product
Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Vitaros (Alprostadil Cream)
Other Products
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Viagra (sildenafil citrate) Segment is Expected to Dominate the Market in the Forecast Period

The overall impact on bulk supply is reported to be overwhelming in all drugs and elsewhere countries. Extended controls from the implementation of measures to combat the spread of COVID-19 have had a two-pronged effect on the supply of bulk supply of drugs. Some countries, such as Italy and Central Asian countries, have experienced a sharp decline in drug supply.

Sildenafil, sold in the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. Its effectiveness in treating sexual dysfunction in women has not been demonstrated. Sildenafil (Viagra) is the most common drug used as first-line therapy in the treatment of erectile dysfunction.

Sildenafil (Viagra) is most effective when taken on an empty stomach one hour before sex. It is effective for four to five hours or more if you have mild to moderate erectile dysfunction. In June 2019, Lupin received approval for its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.’s Viagra Tablets, 25 mg, 50 mg, and 100 mg.

Only 21 years after it was discovered, the sale of a prestigious drug has declined. Pfizer lost exclusive rights to the drug in December 2017, bringing floods of generic drugs. The sales of the drug fell 73% a year in 2018 from USD 789 million to USD 217 million. Pfizer said in a fourth-quarter financial report that the sales of the drug came down due to the generics that entered the market. In addition, barriers such as patients’ neglect in relation to the disease and stagnant growth without progress in the segment restrain the market growth.

Erectile Dysfunction Drugs Market Latest Trends

North America is Expected to Dominate the Market

North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED, and the presence of better healthcare infrastructure. According to the United States Census Bureau’s Statistics as of 2020, the total number of men aged 60-65 was recorded to be 9.86 million. The rise in the geriatric men population is expected to increase the number of patients suffering from ED, as it is very common in men above age 40. The availability of various ED drugs through over-the-counter (OTC) and online channels is a key factor for the dominance of these regions.

According to the results of the research conducted by Dimension Clinic, this health problem affects about 6 million men in Mexico. Meanwhile, only about 15% of them turn for medical help to normalize their sex life.

There are some companies making advancements in terms of the time taken by patients to take the pill before sexual activity. Lupin launched Sildenafil tablets, a generic version of Pfizer's Viagra, used for the treatment of erectile dysfunction in the US market in 2019. In the case of the United States, several companies collaborate with domestic players having extensive market shares in the country. Thus, companies get exclusive rights for marketing, which benefits this market significantly.

Erectile Dysfunction Drugs Market Share By Region

Competitive Landscape

The market studied is fragmented owing to the presence of the various small and large market players. Some of the market players are Apricus Biosciences Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline PLC, Metuchen Pharmaceuticals LLC, Pfizer Inc., S.K. Chemicals Co. Ltd, Teva Pharmaceutical Industries Ltd, and VIVUS Inc.

Recent Developments

In December 2020, Glenmark Pharma received the final approval from the US health regulator for Tadalafil tablets, which are used to treat erectile dysfunction and enlarged prostate.

In June 2020, Launch Medical and GAINSWave announced the resolution of their lawsuit and started working together to market their revolutionary home-use acoustic wave device called The Phoenix for the treatment of erectile dysfunction.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Adoption of a Sedentary Lifestyle Along with the Associated Stress

      2. 4.2.2 Rising Geriatric Population

      3. 4.2.3 Comorbidity between Erectile Dysfunction and Heart Diseases and Diabetes

    3. 4.3 Market Restraints

      1. 4.3.1 Reluctance of Patients to Seek Treatment

      2. 4.3.2 Poor Patient Adherence to ED Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 Viagra (sildenafil citrate)

      2. 5.1.2 Cialis (Tadalafil)

      3. 5.1.3 Levitra/Staxyn (vardenafil)

      4. 5.1.4 Stendra/Spedra (avanafil)

      5. 5.1.5 Zydena (udenafil)

      6. 5.1.6 Vitaros (Alprostadil Cream)

      7. 5.1.7 Other Products

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Apricus Biosciences Inc.

      2. 6.1.2 Bayer AG

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 Ferring Pharmaceuticals

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Metuchen Pharmaceuticals LLC

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 S.K. Chemicals Co. Ltd

      9. 6.1.9 Teva Pharmaceutical Industries Ltd

      10. 6.1.10 VIVUS Inc.

      11. 6.1.11 Lupin Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Erectile Dysfunction Drugs Market market is studied from 2018 - 2026.

The Global Erectile Dysfunction Drugs Market is valued at 3625 Million USD in 2018.

The Global Erectile Dysfunction Drugs Market is valued at 2948 Million USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Eli Lilly and Company, Metuchen Pharmaceuticals, LLC, Pfizer Inc., GlaxoSmithKline plc., Bayer AG are the major companies operating in Global Erectile Dysfunction Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!